Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Immunotherapy targeting EBV-expressing lymphoproliferative diseases.

Bollard CM, Cooper LJ, Heslop HE.

Best Pract Res Clin Haematol. 2008 Sep;21(3):405-20. doi: 10.1016/j.beha.2008.06.002. Review.

PMID:
18790446
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Immunotherapy for Epstein-Barr virus-associated cancers in children.

Straathof KC, Bollard CM, Rooney CM, Heslop HE.

Oncologist. 2003;8(1):83-98. Review.

PMID:
12604735
[PubMed - indexed for MEDLINE]
Free Article
3.

Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas.

Heslop HE.

Hematology Am Soc Hematol Educ Program. 2005:260-6.

PMID:
16304390
[PubMed - indexed for MEDLINE]
Free Article
4.

Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.

Davis JE, Moss DJ.

Tissue Antigens. 2004 Apr;63(4):285-92. Review.

PMID:
15009802
[PubMed - indexed for MEDLINE]
5.

Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.

Sun Q, Burton R, Reddy V, Lucas KG.

Br J Haematol. 2002 Sep;118(3):799-808.

PMID:
12181048
[PubMed - indexed for MEDLINE]
6.

EBV-related lymphomas: new approaches to treatment.

Kanakry JA, Ambinder RF.

Curr Treat Options Oncol. 2013 Jun;14(2):224-36. doi: 10.1007/s11864-013-0231-y.

PMID:
23549980
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.

Straathof KC, Leen AM, Buza EL, Taylor G, Huls MH, Heslop HE, Rooney CM, Bollard CM.

J Immunol. 2005 Sep 15;175(6):4137-47. Erratum in: J Immunol. 2005 Nov 1;175(9):6238.

PMID:
16148164
[PubMed - indexed for MEDLINE]
Free Article
8.

Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.

Leong IT, Fernandes BJ, Mock D.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Aug;92(2):184-93.

PMID:
11505266
[PubMed - indexed for MEDLINE]
9.

T-cell therapies for Epstein-Barr virus-associated lymphomas.

El-Bietar J, Bollard C.

Pediatr Hematol Oncol. 2011 Nov;28(8):627-39. doi: 10.3109/08880018.2011.628367. Review.

PMID:
22023461
[PubMed - indexed for MEDLINE]
10.

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE.

J Exp Med. 2004 Dec 20;200(12):1623-33.

PMID:
15611290
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.

Adhikary D, Behrends U, Boerschmann H, Pfünder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J.

PLoS One. 2007 Jul 4;2(7):e583. Review.

PMID:
17611619
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease.

Kohrt H, Johannsen A, Hoppe R, Horning SJ, Rosenberg SA, Advani R, Lee PP.

Oncol Res. 2009;18(5-6):287-92.

PMID:
20225766
[PubMed - indexed for MEDLINE]
13.

Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.

Rooney CM, Smith CA, Heslop HE.

Mol Med Today. 1997 Jan;3(1):24-30. Review.

PMID:
9021739
[PubMed - indexed for MEDLINE]
14.

CD4+ T cell responses in the immune control against latent infection by Epstein-Barr virus.

Paludan C, Münz C.

Curr Mol Med. 2003 Jun;3(4):341-7. Review.

PMID:
12776989
[PubMed - indexed for MEDLINE]
15.

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.

Roskrow MA, Suzuki N, Gan Yj, Sixbey JW, Ng CY, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM.

Blood. 1998 Apr 15;91(8):2925-34.

PMID:
9531603
[PubMed - indexed for MEDLINE]
Free Article
16.

Regulatory T cells and EBV associated malignancies.

Li J, Qian CN, Zeng YX.

Int Immunopharmacol. 2009 May;9(5):590-2. doi: 10.1016/j.intimp.2009.01.015. Epub 2009 Jan 29. Review.

PMID:
19539572
[PubMed - indexed for MEDLINE]
17.

Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.

Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP.

Cancer Res. 2001 Aug 15;61(16):6219-26.

PMID:
11507075
[PubMed - indexed for MEDLINE]
Free Article
18.

Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.

Huls MH, Rooney CM, Heslop HE.

Acta Haematol. 2003;110(2-3):149-53. Review.

PMID:
14583675
[PubMed - indexed for MEDLINE]
19.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, Zhang L, Heslop HE, Brenner MK, Dotti G.

Blood. 2007 Oct 1;110(7):2620-30. Epub 2007 May 16.

PMID:
17507664
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.

Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, Greenberg PD.

Blood. 1997 Mar 15;89(6):1978-86.

PMID:
9058719
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk